We are learning that myeloproliferative neoplasms affect patients in different ways, even beyond whether they have a diagnosis of polycythemia vera (PV), essential thrombocythemia (ET), or primary or secondary myelofibrosis. In this interview, Dr. Claire Harrison explains the many different aspects of MPNs and how testing is advancing so that we can better understand how and why the disease may manifest differently for each patient. She also discusses how this may affect treatment choices. Watch now.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…